EUVIMEDEUVIMED entdecken
Multizentrische Studie

Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis

Alessandro Brunelli iD, Alessio Mariolo, Clemens Aigner iD, David Gomez De Antonio, Marcelo Jimenez, Hanan Hemead, Ross Hoffman, Joshil Lodhia, Marco Nardini, Giovanni Mattioni, Katharina Sinn, Mir Alireza Hoda und 15 weitere

European Journal of Cardio-Thoracic Surgery · 2025

DOI: 10.1093/ejcts/ezaf343 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Alessandro Brunelli und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, St. James's University Hospital Leeds, Leeds LS9 7TF, United Kingdom. Hauptthemen laut MEDLINE: Nivolumab, Lung Neoplasms, Neoadjuvant Therapy, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the real clinical practice surgical outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre European cohort of patients.

Methods

Retrospective analysis on consecutive patients treated in 6 tertiary referral hospitals in Europe with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB non-small cell lung cancer (March 2023-December 2024). Surgical and pathological outcomes were assessed.

Results

A total of 340 patients started neoadjuvant treatment. Three hundred seventeen patients (93.2%) were able to proceed to surgery. Forty-seven percent of patients had surgery more than 6 weeks after completion of the last neoadjuvant cycle. Two hundred eight operations (66%) were started using a minimally invasive approach with a conversion rate of 18%. The most frequent resection was lobectomy in 86% of patients. Ninety-day postoperative mortality rate was 2.5%. The pathologic complete response occurred in 95 patients (30% of the surgical patients), major pathologic response in 167 patients (52.7% of the surgical patients). The incidence of pathologic complete response (P = .78) and major pathologic response (P = .26) were similar in patients with clinical stage II and III. Pathologic complete response rate was higher in patients with programmed death-ligand 1 (PD-L1) ≥ 50% compared to those with PD-L1 < 50% (37.5% vs 27.2%, P = .082). A higher pathologic complete response (39% vs 23%, P = .004) and major pathologic response (66% vs 45%, P = .001) were observed in squamous vs non-squamous histology tumours.

Conclusions

The use of neoadjuvant nivolumab in association with platinum-based chemotherapy in the real clinical practice is safe and effective. Our real clinical practice data represent valuable information to be used during multidisciplinary treatment selection for clinical stage II and III resectable non-small cell lung cancer and shared decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabLung NeoplasmsNeoadjuvant TherapyCarcinoma, Non-Small-Cell LungPneumonectomyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedEuropeNeoplasm StagingTreatment OutcomeAntineoplastic Agents, ImmunologicalChemotherapy, Adjuvant

Stichwörter der Autor:innen

chemotherapyimmunotherapylung cancerneoadjuvantsurgerytargeted therapy

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Thoracic Surgery, St. James's University Hospital Leeds, Leeds LS9 7TF, United Kingdom.
  • Department of Thoracic Surgery, Curie-Montsouris Thoracic Institute, Institut Mutualiste Montsouris, 75014, Paris, France.
  • Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, A-1090, Vienna, Austria.
  • Thoracic Surgery Department, Hospital Universitario Puerta de Hierro-28222 Majadahonda, Madrid, Spain.
  • Service of Thoracic Surgery, Salamanca University Hospital, Salamanca Institute of Biomedical Research (IBSAL), 37007, Salamanca, Spain.
  • Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, L14 3PE, Liverpool, United Kingdom.

ORCID-Profile: Alessandro Brunelli, Clemens Aigner, Kevin Franks, Nicolas Girard, Michael Shackcloth

Zitieren

APA

Brunelli, A., Mariolo, A., Aigner, C., De Antonio, D. G., Jimenez, M., Hemead, H., Hoffman, R., Lodhia, J., Nardini, M., Mattioni, G., Sinn, K., Hoda, M. A., Novoa, N., Davila, G. R., Gomez-Hernandez, M. T., Rivas-Duarte, C., Bhatnagar, P., Clarke, K., Escriu, C., …, & Shackcloth, M. (2025). Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf343

Vancouver

Brunelli A, Mariolo A, Aigner C, De Antonio DG, Jimenez M, Hemead H, et al. Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf343

BibTeX
@article{Brunelli2025,
  author = {Brunelli, Alessandro and Mariolo, Alessio and Aigner, Clemens and De Antonio, David Gomez and Jimenez, Marcelo and Hemead, Hanan and Hoffman, Ross and Lodhia, Joshil and Nardini, Marco and Mattioni, Giovanni and Sinn, Katharina and Hoda, Mir Alireza and Novoa, Nuria and Davila, Guillermo Rodriguez and Gomez-Hernandez, Maria Teresa and Rivas-Duarte, Cristina and Bhatnagar, Pooja and Clarke, Katy and Escriu, Carles and Fakih, Omar and Franks, Kevin and Bouaziz, Kheira and Calvo, Virginia and Sereno, Maria and Provencio, Mariano and Girard, Nicolas and Shackcloth, Michael},
  title = {Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2025},
  doi = {10.1093/ejcts/ezaf343}
}
Kostenlos starten →